rss
Gut 59:21-30 doi:10.1136/gut.2009.178558
  • Oesophagus

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial

Table 8

Adverse events

Adverse event Mepolizumab (n = 5) n (%) Placebo (n = 6) n (%)
Any adverse event 2 (40) 2 (33)
Nausea 0 1 (17)
Oesophageal food impaction 0 1 (17)
Vomiting 0 1 (17)
Fatigue 1 (20) 0
Upper respiratory tract infection 1 (20) 0

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. web only data

Latest from Gut Education

Latest from Gut Education

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of Gut.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.